Skip to main content
DARE
NASDAQ Life Sciences

Dare Bioscience Launches First Commercial Product, Reports Q2 Results and Positive Ovaprene Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.37
Mkt Cap
$20.522M
52W Low
$1.13
52W High
$3.78
52W Position info
21% above low
Off High info
64% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

DARE sits 21% above its 52-week low of $1.13.

Summary

Dare Bioscience launched its first commercial product, Flora Sync LF5, and reported Q2 2026 results showing $0.2M revenue and a $3.0M net loss. Positive Ovaprene Phase 3 interim data and DARE-HPV Phase 2 initiation were also announced.


Key Events · Earnings and Guidance · DARE

  • First Commercial Product Launch

    Flora Sync LF5 launched through the DARE Health Hub, marking the company's first directly commercialized product, with revenue beginning in July 2026.

  • Q2 2026 Financial Results

    Revenue was $0.2 million, net loss was $3.0 million, and cash and cash equivalents were $12.6 million as of June 30, 2026, with a working capital deficit of $0.2 million.

  • Positive Ovaprene Phase 3 Interim Data

    The independent Data Safety Monitoring Board recommended the pivotal Phase 3 study continue without modification after positive interim results.

  • DARE-HPV Phase 2 Study Initiated

    A Phase 2 study for DARE-HPV, funded by an ARPA-H award, has been initiated and is expected to enroll approximately 100 women, with topline results expected in 2027.


Analysis · DARE · Life Sciences

Dare Bioscience reported Q2 2026 results alongside a commercial inflection: its first directly commercialized product, Flora Sync LF5, launched and began generating revenue in July. The company also disclosed positive interim Phase 3 Ovaprene data and initiation of the DARE-HPV Phase 2 study. Cash stands at $12.6 million with a working capital deficit of $0.2 million, and the company faces a Nasdaq delisting notice from July 2026. The launch and pipeline progress are meaningful for a micro-cap company transitioning from development to commercialization, but the financial position remains tight.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DARE was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $1.13 to $3.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DARE - Latest Insights

DARE
Oct 06, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.844
Real-time Price: $0.6096 info
Change: -$0.2344 (-28%) info
Market Cap: $11.99M info
DARE
Oct 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8428
Real-time Price: $0.6096 info
Change: -$0.2332 (-28%) info
Market Cap: $11.99M info
DARE
Sep 23, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.8074
Real-time Price: $0.6096 info
Change: -$0.1978 (-24%) info
Market Cap: $11.99M info
DARE
Aug 26, 2026, 5:15 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $0.810
Real-time Price: $0.6096 info
Change: -$0.2004 (-25%) info
Market Cap: $11.99M info
DARE
Aug 17, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.900
Real-time Price: $0.6096 info
Change: -$0.2904 (-32%) info
Market Cap: $11.99M info